Description

Generics in Canada Description

Generics in Canada industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Canadian generics market is forecast to generate total revenues of $4.2bn in 2016, representing a compound annual rate of change (CARC) of -0.3% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 3.2% between 2012 and 2016, to reach a total of 62.9% of total pharma volume in 2016.

Pricing issues have led to overall value decline in recent years. In Canada, the average cost of a generic subscription has fallen in recent years although, despite this, Canadians are still paying more for generics than patients in other countries.

Scope

Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Canada

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Canada